Aa
RG7128 80% Und at 12 Weeks
Pharmasset shares rise on positive study results
Shares Pharmasset Inc. rose Wednesday after the company said the hepatitis C drug candidate key goals in a midstage study.
THE SPARK: Pharmasset RG7128 met safety and tolerability goals in the Phase 2b clinical trial, which involved 408 patients. The interim data also showed that 80 percent of patients had undetectable levels of the virus after receiving a 12-week regimen, compared with 50 percent taking the current standard of care.
THE BIG PICTURE: Pharmasset is a clinical-stage company, with no products on the market. RG7128 is the most advance product candidate it has in the partnership with Roche.
THE ANALYSIS: "We believe the safety, efficacy and resistance profiles revealed today are very encouraging, and that RG7128 is now a further, de-risked program," said Wedbush analyst Y. Katherine Xu, while reaffirming an "Outperform" rating with a $44 price target.
SHARE ACTION: Up rose $1.22, or 4.2 percent, to $30.50 in afternoon trading. The stock has traded between $10.15 and $33.50 over the last 52 weeks.
Shares Pharmasset Inc. rose Wednesday after the company said the hepatitis C drug candidate key goals in a midstage study.
THE SPARK: Pharmasset RG7128 met safety and tolerability goals in the Phase 2b clinical trial, which involved 408 patients. The interim data also showed that 80 percent of patients had undetectable levels of the virus after receiving a 12-week regimen, compared with 50 percent taking the current standard of care.
THE BIG PICTURE: Pharmasset is a clinical-stage company, with no products on the market. RG7128 is the most advance product candidate it has in the partnership with Roche.
THE ANALYSIS: "We believe the safety, efficacy and resistance profiles revealed today are very encouraging, and that RG7128 is now a further, de-risked program," said Wedbush analyst Y. Katherine Xu, while reaffirming an "Outperform" rating with a $44 price target.
SHARE ACTION: Up rose $1.22, or 4.2 percent, to $30.50 in afternoon trading. The stock has traded between $10.15 and $33.50 over the last 52 weeks.
I think r7128 is the most promising drug currently in phase 2 studies. I hope that they can now move on to phase 3 and get it out here to us sooooonest!
dointime
dointime
This can only be a positive incentive for more and more pharmaceutical companies to come up with a less and less brutal treatment plan"
I agree just as much as people like to complain about big pharma they are the future for heppers (and other diseases too) and without them and their profit incentives - nothing would ever get developed would it?
I agree just as much as people like to complain about big pharma they are the future for heppers (and other diseases too) and without them and their profit incentives - nothing would ever get developed would it?
RG7128 in my view will be the next best PI , because of its saftey profile and bacuse
it is cross geno. ( it did show some kidney problems in resus monkeys)
It is a triple tx , RG7128 +SOC.
What counts here are SVR rates , not hot air on the stock market.
b
it is cross geno. ( it did show some kidney problems in resus monkeys)
It is a triple tx , RG7128 +SOC.
What counts here are SVR rates , not hot air on the stock market.
b
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
This can only be a positive incentive for more and more pharmaceutical companies to come up with a less and less brutal treatment plan... I’m sure all the pharmaceutical companies know that the winner will be the one with a treatment with NO side effects...
Mag